A Phase II Study in Healthy Adults (19-64 Years of Age) to Assess the Safety, Reactogenicity and Immunogenicity of Sequential or Simultaneous Intramuscular Administration of an AS03-adjuvanted A/H7N9 Inactivated Influenza Vaccine With Seasonal Influenza Vaccine
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2019
Price : $35 *
At a glance
- Drugs Influenza A virus H7N9 vaccines (Primary) ; Influenza virus vaccine
- Indications Influenza A virus H7N9 subtype
- Focus Adverse reactions; Pharmacodynamics
- 01 Aug 2019 Status changed from active, no longer recruiting to completed.
- 06 Jun 2019 Planned primary completion date changed from 20 May 2019 to 19 Jul 2019.
- 19 Jul 2018 Status changed from recruiting to active, no longer recruiting.